Unlocking the Power of Cancer Treatment with Dr Dennis Slamon's Visionary Approach We weren’t able to create a summary for you. Refresh your page to try again. The Albert and Mary Lasker Foundation honored Slamon and colleagues H. Michael Shepard and Axel Ullrich for demonstrating that monoclonal antibodies were a viable and effective strategy to treat solid tumors, opening a new path to develop and deploy antibodies to treat cancer . The Albert and Mary Lasker Foundation honored Slamon and colleagues H. Michael Shepard and Axel Ullrich for demonstrating that monoclonal antibodies were a viable and effective strategy to treat solid tumors, opening a new path to develop and deploy antibodies to treat cancer . Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. The Albert and Mary Lasker Foundation honored Slamon and colleagues H. Michael Shepard and Axel Ullrich for demonstrating that monoclonal antibodies were a viable and effective strategy to treat solid tumors, opening a new path to develop and deploy antibodies to treatcancer. Nov 25, 2023 · When Dr. Abraham asked about the intersection of industry and academic medicine in the drug development process, Dr. Slamon responded: “For a long time, industry had its own big science groups that were doing their own internal research, and they still do. He also shares insights on the evolution of targeted therapies, the growing promise of early detection, and his advice for the next generation of cancer researchers.
